How many patients do you manage with Hidradenitis Suppurativa?

On a scale of 1 to 10 (with 10 being ecstatic), how excited are you for Izokibep (Affibody® IL-17A Inhibitor), Povorcitinib (INCB054707, JAK1 Inhibitor), and Sonelokimab (IL-17A/F Nanobody) as potential treatments for Hidradenitis Suppurativa?

Given the positive statistical results of MIRA and VELA-1 and the failure of the VELA-2 trail to be statistically significant, is it your belief that the FDA will or will not approve the Sonelokimab for HS?

MoonLake Therapeutics argues that Sonelokimab albumin-binding nanobody structure improves drug distribution to inflamed tissue.  Please comment on your confidence in this hypothesis.

Assuming FDA approval of Sonelokimab for HS, based on the clinical trial results to date as presented in MIRA, VELA-1 and VELA-2, how would you slot the drug into your treatment regimen for patients?  Would you recommended Sonelokimab to patients before or after Bimekizumab and Cosentyx or other drugs you prescribe for HS?

Do you have a most likely explanation for the very high placebo response rate in the  VELA-2 trial for Sonelokimab?  To what degree does this explanation undermine the fact that drug responder rates in VELA-1 and VELA-2 were very similar?

What do you believe is the key inflammatory pathway(s) for HS?  IL-17A, IL-17F, TNF-α, IL-1β, IL-23? 

Please comment on your impressions of the recently announced 40 week data for VELA-1 and VELA-2 wherein HISCR-75 was reported at 62% and HISCR-100 was reported at 32%. Would you consider this best in class results? Were there any other particularly noteworthy results in this data update that impressed or disappointed you (e.g.  HiSQOL items, worst skin pain NRS, change in DLQI)